Jefferies Starts Adlai Nortye Ltd. (ANL) at Buy

Jefferies analyst Maury Raycroft initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and a price target of $31.00.

The analyst comments "AN9025 has a pot’ly best-in-class pan-RAS profile, w/ durable tumor PD on QW dosing offering a path to a wider TI and the tolerability needed for 1L combinations. We expect 1H27 QD data to show in line-to-better efficacy/ safety vs daraxonrasib, while the still-early QW profile will be the key focus. Combined with longer-term optionality from AN4035, a CEACAM5 ADC w/ panRASi payload, ANL has multiple paths to emerge as a next-gen pan-RAS leader."

For an analyst ratings summary and ratings history on Adlai Nortye Ltd. click here. For more ratings news on Adlai Nortye Ltd. click here.

Shares of Adlai Nortye Ltd. closed at $14.70 yesterday.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Citrini Research acquired by Semianalysis
• Cronos Group extends cannabis acquisition deadline to October 2026